Radiotherapy and immunotherapy: A beneficial liaison?

Nature Reviews Clinical Oncology

Volumn 14, Issue 6, 2017, Pages 365-379

  Weichselbaum, Ralph R ^a   Liang, Hua ^a   Deng, Liufu ^a   Fu, Yang Xin ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; ATEZOLIZUMAB; AVELUMAB; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROTEIN ANTIBODY; PROTEIN INHIBITOR; REGN 2810; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COLORECTAL CANCER; ESOPHAGUS CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; LIVER METASTASIS; LUNG CANCER; MERKEL CELL CARCINOMA; METASTATIC BREAST CANCER; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PONTINE GLIOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ADAPTIVE IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; RADIATION RESPONSE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; COMBINED MODALITY THERAPY; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85009820249     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.211     Document Type: Review

References (248)

1. Orth, M. et al. Current concepts in clinical radiation oncology. Radiat. Environ. Biophys. 53, 1-29 (2014).
2. Hoskin, P. J. & Bhattacharya, I. S. Protons and more: state of the art in radiotherapy. Clin. Med. (Lond.) 14, s61-s65 (2014).
3. Bast, R. C. Holland-Frei Cancer Medicine 9th edn (John Wiley & Sons, 2016).
4. Kufe, D. W. et al. Cancer Medicine 6th edn (BC Decker, 2003).
5. Regaud, C. The influence of the duration of irradiation on the changes produced in the testicle by radium. Int. J. Radiat. Oncol. Biol. Phys. 2, 565-567 (1977).
6. Coutard, H. Principles of x ray therapy of malignant diseases. Lancet 224, 1-8 (1934).
7. Coutard, H. The results and methods of treatment of cancer by radiation. Ann. Surg. 106, 584-598 (1937).
8. Whelan, T. J. et al. Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362, 513-520 (2010).
9. Adebahr, S. et al. LungTech, an EORTC phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br. J. Radiol. 88, 20150036 (2015).
10. Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8-10 (1995).
11. Okunieff, P. et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 45, 808-817 (2006).
12. Milano, M. T., Philip, A. & Okunieff, P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int. J. Radiat. Oncol. Biol. Phys. 73, 832-837 (2009).
13. Salama, J. K. et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118, 2962-2970 (2012).
14. Fumagalli, I. et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat. Oncol. 7, 164 (2012).
15. Corbin, K. S., Hellman, S. & Weichselbaum, R. R. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J. Clin. Oncol. 31, 1384-1390 (2013).
16. Kao, J. et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol. 9, 145-153 (2014).
17. Decaestecker, K. et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 14, 671 (2014).
18. Niibe, Y. et al. Stereotactic body radiotherapy results for pulmonary oligometastases: a two-institution collaborative investigation. Anticancer Res. 35, 4903-4908 (2015).
19. Norkus, D. et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat. Oncol. 8, 206 (2013).
20. Loblaw, A. et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother. Oncol. 107, 153-158 (2013).
21. Viani, G. A. et al. Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment. Radiat. Oncol. 8, 94 (2013).
22. Aluwini, S. et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet. Oncol. 16, 274-283 (2015).
23. Anand, A. K. et al. Hypofractionated stereotactic body radiotherapy in spinal metastasis - with or without epidural extension. Clin. Oncol. 27, 345-352 (2015).
24. Crane, C. H. Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. J. Radiat. Res. http://dx.doi.org/10.1093/jrr/rrw016 (2016).
25. Hellstrom, K. E., Hellstrom, I., Kant, J. A. & Tamerius, J. D. Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J. Exp. Med. 148, 799-804 (1978).
26. North, R. J. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J. Exp. Med. 164, 1652-1666 (1986).
27. Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862-870 (2004).
28. Demaria, S., Bhardwaj, N., McBride, W. H. & Formenti, S. C. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63, 655-666 (2005).
29. Lugade, A. A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516-7523 (2005).
30. Zhang, B. et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49-55 (2007).
31. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-595 (2009).
32. Burnette, B., Fu, Y. X. & Weichselbaum, R. R. The confluence of radiotherapy and immunotherapy. Frontiers Oncol. 2, 143 (2012).
33. Frey, B. et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr. Med. Chem. 19, 1751-1764 (2012).
34. Formenti, S. C. & Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl Cancer Institute 105, 256-265 (2013).
35. Burnette, B. & Weichselbaum, R. R. Radiation as an immune modulator. Semin. Radiat. Oncol. 23, 273-280 (2013).
36. Demaria, S. & Formenti, S. C. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Frontiers Oncol. 3, 128 (2013).
37. Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687-695 (2014).
38. Lim, J. Y., Gerber, S. A., Murphy, S. P. & Lord, E. M. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells. Cancer Immunol. Immunother. 63, 259-271 (2014).
39. Sharabi, A. B. et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345-355 CIR-14-0196 (2015).
40. Seetharam, S. et al. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int. J. Oncol. 15, 769-773 (1999).
41. Formenti, S. C. et al. Abscopal response in irradiated patients: results of a proof of principle trial. Int. J. Radiat. Oncol. Biol. Phys. 72, S6-S7 (2008).
42. Sharabi, A. B., Tran, P. T., Lim, M., Drake, C. G. & Deweese, T. L. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncol. (Williston Park) 29, 331-340 (2015).
43. Golden, E. B. et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet. Oncol. 16, 795-803 (2015).
44. Park, S. S. et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol. Res. 3, 610-619 (2015).
45. Vanpouille-Box, C. et al. TGFβ Is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232-2242 (2015).
46. Bunt, S. K. et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026 (2007).
47. Meng, Y. et al. Blockade of tumor necrosis factor α signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 70, 1534-1543 (2010).
48. Ahn, G. O. et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl Acad. Sci. USA 107, 8363-8368 (2010).
49. Chiang, C. S. et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Frontiers Oncol. 2, 89 (2012).
50. Schaue, D. & McBride, W. H. T lymphocytes and normal tissue responses to radiation. Frontiers Oncol. 2, 119 (2012).
51. Zitvogel, L. & Kroemer, G. Subversion of anticancer immunosurveillance by radiotherapy. Nat. Immunol. 16, 1005-1007 (2015).
52. Stone, H. B., Peters, L. J. & Milas, L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl Cancer Institute 63, 1229-1235 (1979).
53. Viaud, S. et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71, 661-665 (2011).
54. Gupta, A. et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189, 558-566 (2012).
55. Demaria, S. & Formenti, S. C. Role of T lymphocytes in tumor response to radiotherapy. Frontiers Oncol. 2, 95 (2012).
56. Gerber, S. A. et al. IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am. J. Pathol. 182, 2345-2354 (2013).
57. Gerber, S. A. et al. Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int. J. Cancer 134, 2383-2392 (2014).
58. Yoshimoto, Y. et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE 9, e92572 (2014).
59. Filatenkov, A. et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Cancer Res. 21, 3727-3739 (2015).
60. McBride, W. H. et al. A sense of danger from radiation. Radi. Res. 162, 1-19 (2004).
61. Schaue, D., Kachikwu, E. L. & McBride, W. H. Cytokines in radiobiological responses: a review. Radiat. Res. 178, 505-523 (2012).
62. Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488-2496 (2011).
63. Liu, C. et al. Gamma-ray irradiation impairs dendritic cell migration to CCL19 by down-regulation of CCR7 and induction of cell apoptosis. Int. J. Biol. Sci. 7, 168-179 (2011).
64. Manda, K., Glasow, A., Paape, D. & Hildebrandt, G. Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Frontiers Oncol. 2, 102 (2012).
65. Foulds, G. A., Radons, J., Kreuzer, M., Multhoff, G. & Pockley, A. G. Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Frontiers Oncol. 3, 14 (2013).
66. Park, B., Yee, C. & Lee, K. M. The effect of radiation on the immune response to cancers. Int. J. Mol. Sci. 15, 927-943 (2014).
67. Zitvogel, L., Kepp, O. & Kroemer, G. Decoding cell death signals in inflammation and immunity. Cell 140, 798-804 (2010).
68. Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860-875 (2012).
69. Krysko, O., Love Aaes, T., Bachert, C., Vandenabeele, P. & Krysko, D. V. Many faces of DAMPs in cancer therapy. Cell Death Dis. 4, e631 (2013).
70. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
71. Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).
72. Hallahan, D. E., Spriggs, D. R., Beckett, M. A., Kufe, D. W. & Weichselbaum, R. R. Increased tumor necrosis factor α mRNA after cellular exposure to ionizing radiation. Proc. Natl Acad. Sci. USA 86, 10104-10107 (1989).
73. Vlodavsky, I. et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 9, 203-226 (1990).
74. Hallahan, D. E. et al. Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res. 51, 4565-4569 (1991).
75. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
76. Fu, Y. et al. Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int. J. Mol. Sci. 14, 14105-14118 (2013).
77. Pasi, F., Paolini, A., Nano, R., Di Liberto, R. & Capelli, E. Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines. Biomed Res. Int. 2014, 453497 (2014).
78. Matsumura, S. et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099-3107 (2008).
79. Meng, Y. et al. Ad. Egr-TNF and local ionizing radiation suppress metastases by interferon-β-dependent activation of antigen-specific CD8+ T cells. Mol. Ther. 18, 912-920 (2010).
80. Taieb, J. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12, 214-219 (2006).
81. Chakraborty, M. et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64, 4328-4337 (2004).
82. Garnett, C. T. et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64, 7985-7994 (2004).
83. Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259-1271 (2006).
84. Characiejus, D. et al. Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res. 31, 699-703 (2011).
85. Characiejus, D. et al. Prediction of response in cancer immunotherapy. Anticancer Res. 31, 639-647 (2011).
86. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
87. Liu, S. et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 14, R48 (2012).
88. Anitei, M. G. et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin. Cancer Res. 20, 1891-1899 (2014).
89. Dushyanthen, S. et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 13, 202 (2015).
90. Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7-19 (2015).
91. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
92. Kim, J. Y. et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med. 38, 474-484 (2006).
93. Pilones, K. A. et al. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin. Cancer Res. 15, 597-606 (2009).
94. Gaipl, U. S. et al. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 6, 597-610 (2014).
95. Ames, E. et al. Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. Oncoimmunology 4, e1036212 (2015).
96. Hermanson, D. L. & Kaufman, D. S. Utilizing chimeric antigen receptors to direct natural killer cell activity. Frontiers Immunol. 6, 195 (2015).
97. Carotta, S. Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Frontiers Immunol. 7, 152 (2016).
98. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer 4, 540-550 (2004).
99. Cummings, R. J., Mitra, S., Foster, T. H. & Lord, E. M. Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat. Res. 171, 687-697 (2009).
100. Moravan, M. J., Olschowka, J. A., Williams, J. P. & O'Banion, M. K. Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain. Radiat. Res. 176, 459-473 (2011).
101. Yang, X. et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37-48 (2014).
102. Facciabene, A., Motz, G. T. & Coukos, G. T-Regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162-2171 (2012).
103. Kachikwu, E. L. et al. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128-1135 (2011).
104. Persa, E., Balogh, A., Safrany, G. & Lumniczky, K. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 368, 252-261 (2015).
105. Balogh, A. et al. The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm Res. 62, 201-212 (2013).
106. McFarland, H. I. et al. Regulatory T cells in γ irradiation-induced immune suppression. PLoS ONE 7, e39092 (2012).
107. Price, J. G. et al. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat. Immunol. 16, 1060-1068 (2015).
108. Fadul, C. E. et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J. Immunother. 34, 382-389 (2011).
109. Schuler, P. J. et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin. Cancer Res. 19, 6585-6596 (2013).
110. Qinfeng, S. et al. In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat. Res. 179, 584-589 (2013).
111. Bouquet, F. et al. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 17, 6754-6765 (2011).
112. Schaue, D., Xie, M. W., Ratikan, J. A. & McBride, W. H. Regulatory T cells in radiotherapeutic responses. Frontiers Oncol. 2, 90 (2012).
113. Formenti, S. C., Demaria, S., Barcellos-Hoff, M. H. & McBride, W. H. Subverting misconceptions about radiation therapy. Nat. Immunol. 17, 345 (2016).
114. Condamine, T., Ramachandran, I., Youn, J. I. & Gabrilovich, D. I. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 66, 97-110 (2015).
115. Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125, 3356-3364 (2015).
116. Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208-220 (2016).
117. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
118. Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
119. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
120. Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105-115 (2013).
121. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
122. Weis, S. M. & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359-1370 (2011).
123. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012).
124. Crittenden, M. R. et al. Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS ONE 7, e39295 (2012).
125. Xu, J. et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782-2794 (2013).
126. Crittenden, M. R. et al. The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PLoS ONE 8, e69527 (2013).
127. Vatner, R. E. & Formenti, S. C. Myeloid-derived cells in tumors: effects of radiation. Semin. Radiat. Oncol. 25, 18-27 (2015).
128. Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355 (2008).
129. Mills, C. D. M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 32, 463-488 (2012).
130. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
131. Inoue, T. et al. CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis. Eur. Respir. J. 24, 49-56 (2004).
132. Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589-602 (2013).
133. Shiao, S. L. et al. TH2-polarized CD4+ T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol. Res. 3, 518-525 CIR-14-0232 (2015).
134. Seifert, L. et al. Radiation therapy induces macrophages to suppress immune responses against pancreatic tumors in mice. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2016.02.070 (2016).
135. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012).
136. Schaue, D. et al. Radiation and inflammation. Seminars Radiat. Oncol. 25, 4-10 (2015).
137. Medrek, C., Ponten, F., Jirstrom, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306 (2012).
138. Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379-5388 (2009).
139. Verbrugge, I. et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72, 3163-3174 (2012).
140. Demaria, S. & Formenti, S. C. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Frontiers Oncol. 2, 153 (2012).
141. Gupta, A. et al. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology 1, 1610-1611 (2012).
142. Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA 105, 18490-18495 (2008).
143. Khodarev, N. N. et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 4, e5821 (2009).
144. Khodarev, N. N., Roizman, B. & Weichselbaum, R. R. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18, 3015-3021 (2012).
145. Minn, A. J. Interferons and the immunogenic effects of cancer therapy. Trends Immunol. 36, 725-737 (2015).
146. Deng, L. et al. STING-dependent cytosolic DNA Sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843-852 (2014).
147. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788-792 (2009).
148. Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 5, ra20 (2012).
149. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786-791 (2013).
150. Li, X. D. et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390-1394 (2013).
151. Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150, 803-815 (2012).
152. Sharma, S. et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35, 194-207 (2011).
153. Coban, C. et al. Novel strategies to improve DNA vaccine immunogenicity. Curr. Gene Ther. 11, 479-484 (2011).
154. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842 (2014).
155. Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409-425 (2015).
156. Thomas, L. Cellular and humoral aspects of the hypersensitive states; a symposium held at the New York Academy of Medicine (Hoeber, 1959).
157. Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007).
158. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
159. Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16-25 (2014).
160. Klein, E. Tumour immunology; escape mechanisms. Ann. Inst. Pasteur 122, 593-602 (1972).
161. Hyman, R. Genetic alterations in tumor cells resulting in their escape from the immune response. Cancer Chemother. Rep. 58, 431-439 (1974).
162. Yutoku, M., Fuji, H., Grossberg, A. L. & Pressman, D. An experimental model for evaluation of factors in tumor escape from immunological attack. Cancer Res. 35, 734-739 (1975).
163. Bruttel, V. S. & Wischhusen, J. Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Frontiers Immunol. 5, 360 (2014).
164. Liang, H. et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J. Immunol. 190, 5874-5881 (2013).
165. Liang, H., Deng, L., Burnette, B., Weichselbaum, R. R. & Fu, Y. X. Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. Oncoimmunology 2, e25668 (2013).
166. Schietinger, A. & Greenberg, P. D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35, 51-60 (2014).
167. Shaked, Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/ nrclinonc.2016.57 (2016).
168. Suit, H. D. & Walker, A. M. Assessment of the response of tumours to radiation: clinical and experimental studies. Br. J. Cancer. Suppl. 4, 1-10 (1980).
169. Early Breast Cancer Trialists' Collaborative, G. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 378, 1707-1716 (2011).
170. Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
171. Char, D. H., Kroll, S., Phillips, T. L. & Quivey, J. M. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 109, 1850-1854 (2002).
172. Chao, K. S. et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 312-321 (2003).
173. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562-567 (2003).
174. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467-477 (2008).
175. Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458-5468 (2014).
176. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
177. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
178. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384-3391 (2015).
179. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
180. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
181. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
182. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
183. Wolchok, J. D. & Chan, T. A. Cancer: antitumour immunity gets a boost. Nature 515, 496-498 (2014).
184. Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C. & Demaria, S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 33, 7415-7422 (2015).
185. Ruocco, M. G. et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J. Clin. Invest. 122, 3718-3730 (2012).
186. Demaria, S., Pilones, K. A., Formenti, S. C. & Dustin, M. L. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2, e23127 (2013).
187. Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728-734 (2005).
188. Small, E. J. et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13, 1810-1815 (2007).
189. Yang, J. C. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007).
190. Weber, J. S. et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26, 5950-5956 (2008).
191. Weber, J. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591-5598 (2009).
192. Ansell, S. M. et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15, 6446-6453 (2009).
193. Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet. Oncol. 11, 155-164 (2010).
194. O'Day, S. J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712-1717 (2010).
195. Hersh, E. M. et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investigat. Drugs 29, 489-498 (2011).
196. Sharma, P., Wagner, K., Wolchok, J. D. & Allison, J. P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805-812 (2011).
197. Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 3005-3010 (2008).
198. Madan, R. A. et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 501-508 (2012).
199. Sarnaik, A. A. et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 17, 896-906 (2011).
200. McDermott, D. et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol. 24, 2694-2698 (2013).
201. Jochems, C. et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 63, 407-418 (2014).
202. Fong, L. et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69, 609-615 (2009).
203. Le, D. T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382-389 (2013).
204. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
205. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
206. Slovin, S. F. et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 24, 1813-1821 (2013).
207. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700-712 (2014).
208. Di Giacomo, A. M. et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886 (2012).
209. Reck, M. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75-83 (2013).
210. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054 (2012).
211. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
212. Weber, J. et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 13, 7 (2013).
213. Lu, W. et al. Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. Oncol. Lett. 5, 1519-1526 (2013).
214. Chen, J. et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217, 385-393 (2012).
215. Lu, J., Lee-Gabel, L., Nadeau, M. C., Ferencz, T. M. & Soefje, S. A. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J. Oncol. Pharm. Pract. 21, 451-467 (2014).
216. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
217. Brahmer, J. R. PD-1-targeted immunotherapy: recent clinical findings. Clin. Adv. Hematol. Oncol. 10, 674-675 (2012).
218. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
219. Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012).
220. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
221. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
222. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
223. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
224. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
225. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
226. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
227. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013).
228. Weber, J. S. Current perspectives on immunotherapy. Seminars Oncol. 41 (Suppl. 5), S14-29 (2014).
229. Sui, X. et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 6, 19393-19404 (2015).
230. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
231. Sade-Feldman, M. et al. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38, 541-554 (2013).
232. Zhao, X. et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122, 4094-4104 (2012).
233. Dahan, R. et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28, 285-295 (2015).
234. Zeng, J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343-349 (2013).
235. Formenti, S. C. & Demaria, S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84, 879-880 (2012).
236. Sharabi, A. et al. Role of radiation therapy in inducing antigen specific antitumor immune responses when combined with anti-PD1 checkpoint blockade: Mechanism and clinical implications. Int. J. Radiat. Biol. Oncol. Phys. 90, S1 (2014).
237. Dovedi, S. J. & Illidge, T. M. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology 4, e1016709 (2015).
238. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
239. Mole, R. H. Whole body irradiation; radiobiology or medicine? Br. J. Radiol. 26, 234-241 (1953).
240. Siva, S., MacManus, M. P., Martin, R. F. & Martin, O. A. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 356, 82-90 (2015).
241. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
242. Zeng, J., Harris, T. J., Lim, M., Drake, C. G. & Tran, P. T. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res. Int. 2013, 658126 (2013).
243. Hiniker, S. M., Chen, D. S. & Knox, S. J. Abscopal effect in a patient with melanoma. New Engl. J. Med. 366, 2035 (2012).
244. Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y. & Brownell, I. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85, 293-295 (2013).
245. Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A. & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365-372 (2013).
246. Grimaldi, A. M. et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3, e28780 (2014).
247. Chandra, R. A. et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 4, e1046028 (2015).
248. Kaminski, J. M. et al. The controversial abscopal effect. Cancer Treat. Rev. 31, 159-172 (2005).